Intravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study

Clin Infect Dis. 2015 Nov 1;61(9):1441-4. doi: 10.1093/cid/civ575. Epub 2015 Jul 17.


Intravenous artesunate improves survival in severe malaria, but clinical trial data from nonendemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs quinine treatment. Artesunate reduced parasite clearance time and duration of intensive care unit and hospital treatment in European patients with imported severe malaria.

Keywords: Plasmodium falciparum; artesunate; clinical study; quinine; severe malaria.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Adult
  • Antimalarials / administration & dosage*
  • Artemisinins / administration & dosage*
  • Artesunate
  • Europe
  • Female
  • Humans
  • Malaria / drug therapy*
  • Male
  • Quinine / administration & dosage
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome


  • Antimalarials
  • Artemisinins
  • Artesunate
  • Quinine